Biofrontera

Yahoo Finance • last month

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission... Full story

Yahoo Finance • last month

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met... Full story

Yahoo Finance • 2 months ago

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and comme... Full story

Yahoo Finance • 2 months ago

Biofrontera reports Q3 results

* Biofrontera press release [https://seekingalpha.com/filing/38897076] (BFRI [https://seekingalpha.com/symbol/BFRI]): Q3 GAAP EPS of -$0.62. * Revenue of $6.98M (-22.5% Y/Y). MORE ON BIOFRONTERA * Seeking Alpha’s Quant Rating on Bi... Full story

Yahoo Finance • 2 months ago

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expe... Full story

Yahoo Finance • 2 months ago

Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025

WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report fina... Full story

Yahoo Finance • 4 months ago

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will p... Full story

Yahoo Finance • 4 months ago

Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has enga... Full story

Yahoo Finance • 4 months ago

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to form the basis of a supp... Full story

Yahoo Finance • 5 months ago

Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in... Full story

Yahoo Finance • 5 months ago

Biofrontera signals enhanced operating leverage as U.S. independence and new patent reshape outlook

Earnings Call Insights: Biofrontera Inc. (BFRI) Q2 2025 MANAGEMENT VIEW * CEO Hermann Luebbert highlighted a "record breaking" performance in the first half of 2025, driven by a shift in customer segmentation strategy, data-driven sale... Full story

Yahoo Finance • 5 months ago

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financ... Full story

Yahoo Finance • 5 months ago

Biofrontera Inc. Appoints George Jones as Chief Commercial Officer

Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of... Full story

Yahoo Finance • 5 months ago

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financ... Full story

Yahoo Finance • 6 months ago

Biofrontera files to sell 13.6M shares of common stock by selling shareholders

* Biofrontera (NASDAQ:BFRI [https://seekingalpha.com/symbol/BFRI]) filed a prospectus to sale 13.6 million shares of class A common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling shar... Full story

Yahoo Finance • 6 months ago

Biofrontera restructures relationship with Biofrontera AG, backed by $11M investment

Biofrontera (NASDAQ:BFRI [https://seekingalpha.com/symbol/BFRI]) said on Monday that it has acquired [https://seekingalpha.com/pr/20151642-biofrontera-inc-announces-major-restructuring-of-relationship-with-biofrontera-ag-backed-by]all U.S.... Full story

Yahoo Finance • 7 months ago

BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG

WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board o... Full story

Yahoo Finance • 7 months ago

Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book

Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all appro... Full story

Yahoo Finance • 8 months ago

Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization... Full story

Yahoo Finance • 8 months ago

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris

Biofrontera has received patent approval for the revised formulation of Ameluz®, which extends patent protection through to December 2043Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side ef... Full story